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myocardial dysfunction developed in our patient
after the administration of doxorubicin in a single
dose well below that typically associated with car-
diotoxic effects. The rapid improvement in left ven-
tricular function observed in this patient within four
weeks suggests that substantial myocardial stun-
ning was present. Although it is very rare, acute re-
versible left ventricular failure should be considered
in patients in whom respiratory failure or shock de-
velops after the administration of even a single dose
of doxorubicin.
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Cabergoline plus Lanreotide for Ectopic Cushing’s Syndrome
to the editor: The ectopic corticotropin syndrome,
a rare cause of chronic endogenous hypercortisol-
ism, accounts for 15 to 20 percent of corticotropin-
dependent Cushing’s syndrome and 5 to 10 percent
of cases of Cushing’s syndrome overall.1,2 This syn-
drome is often associated with corticotropin-secret-
ing lung carcinoid tumors. The treatment of choice
in cases in which the syndrome is associated with
lung carcinoid is surgery, but the success rate of sur-
gery is limited owing to the persistence of tumor
remnants,3 which frequently necessitate palliative
medical treatment to inhibit adrenal cortisol secre-
tion. Somatostatin analogues have been observed to
be effective in controlling carcinoid corticotropin
secretion4; in contrast, dopamine agonists have not
been used in treatment of the ectopic corticotropin
syndrome. In this report, we describe a patient with
the ectopic corticotropin syndrome due to a lung
carcinoid tumor. After surgery failed, the condition
was successfully managed with a long-acting so-
matostatin analogue, together with a long-acting
dopamine agonist.
A 35-year-old man had a clinical picture sugges-
tive of the ectopic corticotropin syndrome related to
a carcinoid tumor; biochemical and hormonal tests
confirmed the diagnosis. Somatostatin-receptor
scintigraphy revealed abnormal uptake in the anter-
obasal region of the left lung, and computed tomog-
raphy (CT) revealed a lung tumor. Thoracotomy was
performed, and the presence of a corticotropin-pos-
itive, atypical carcinoid tumor was confirmed. After
surgical removal of the tumor, Cushing’s syndrome
persisted, with increased plasma cortisol levels and
increased urinary cortisol excretion. Somatostatin-
receptor scintigraphy showed persistently abnormal
uptake in the left lung, although chest CT revealed
no abnormalities. Since reoperation was not an op-
tion, therapy with the somatostatin analogue lan-
reotide (90 mg per month) was begun, on the basis
of the positive findings on scintigraphy. After six
months, corticotropin and cortisol secretion de-
creased but then stopped responding to treatment,
and after one year, the lanreotide therapy was
stopped. Since reverse-transcriptase–polymerase-
chain-reaction analysis of somatostatin-receptor
and dopamine-receptor expression in a tumor sam-
Figure 1. Urinary Cortisol Levels after Various Treatments in a Patient 
with the Ectopic Corticotropin Syndrome Associated with a Corticotropin-
Secreting Lung Carcinoid.
LAN denotes lanreotide, and CAB cabergoline.
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ple revealed dopamine D2 receptor expression in ad-
dition to expression of somatostatin receptor sub-
type 5, dopamine-agonist therapy with cabergoline
(7 mg per week) was initiated. After six months, cor-
ticotropin and cortisol secretion normalized but
then stopped responding again, and the adminis-
tration of cabergoline was stopped after one year.
In a final attempt at medical therapy, combined
treatment with cabergoline and lanreotide was
started on the basis of the documented interaction
between the dopamine D2 receptor and the soma-
tostatin receptor subtype 5.5 Corticotropin and cor-
tisol secretion rapidly normalized and remained
normal, as did plasma corticotropin and urinary
cortisol levels (Fig. 1).
This case documents the long-term effectiveness
of combined treatment with a somatostatin ana-
logue and a dopamine agonist in a patient who no
longer had a response to either agent alone and sup-
ports the hypothesis that somatostatin and dopa-
mine receptors interact and that somatostatin and
dopamine agonists may potentiate actions.
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